

VISCHER ADVISED POLYNEURON IN ITS SERIES A FINANCING EXTENSION TO CHF 36.5M

Posted on 22 September 2020



Category: [Pharma](#)

Tags: [Ex-Featured](#), [Matthias Staehelin](#), [Moritz Jäggy](#)



Polyneuron Pharmaceuticals, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by autoimmune diseases, extended its Series A by CHF 14m bringing the total to CHF 36.5m. HBM Healthcare Investments joins as additional investor to lead investor Sofinnova Partners and New Enterprise Associates.

VISCHER [advises Polyneuron](#) with a team led by Matthias Staehelin (Partner - pictured) with Moritz Jäggy (Managing Associate), both Corporate.